Skip to main content
SpringerLink
Log in

25+ Observations Over 25+ Years for Surviving and Thriving in the Dietary Supplement Quality Control and/or Perception Versus Reality World

  • Chapter
Integrative Medicine for Breast Cancer

  • 742 Accesses

Abstract

“Vitamin E is dangerous!” “Herbal products have no evidence!” ______ does not treat or cure advanced cancer“? “Supplements don’t do anything, so don’t waste your money!” For almost 30 years I have watched not just patients, but especially some influential clinicians generalize, embellish, and misconstrue data on dietary supplements. This type of commentary just mirrors the lack of objective education in this area, does nothing to improve the clinician and patient relationship, and arguably sends countless individuals to less credible sources for information and misguided sales pitches (as it did through the years for many of my own family members). At the same time, I have watched many in the supplement industry embellish data and supplement efficacy and promote a “we vs. them” contentious milieu that only continues to confuse the public. Again, this acrimonious dichotomy or profound polarization does nothing for overall patient care [1].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Moyad MA. The supplement handbook: a trusted expert’s guide to what works & what’s worthless for more than 100 conditions. New York: Rodale Publishing; 2014.

    Google Scholar 

  2. O’Connor A. New York Attorney General targets supplements at major retailers, 3 Feb 2015. wee.blogs.nytimes.com/2015/02/03/new-york-attorney-general-targets-supplements-at-major-retailers/?_r=0 Accessed 1 June 2015.

    Google Scholar 

  3. Esch M of Associated Press. Supplements industry derides NY attorney general’s DNA tests, 8 Feb 2015. http://abcnews.go.com/Health/wireStory/supplements-industry-derides-ny-attorney-generals-dna-tests-28812984?page=2. Accessed 1 June 2015.

  4. Newmaster SG, Grguric M, Shanmughanandhan D, Ramalingam S, Ragupathy S. DNA barcoding detects contamination and substitution in North American herbal products. BMC Med. 2013;11:222.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  5. US Food and Drug Administration. What is a dietary supplement? www.fda.gov/AboutFDA/Transparency/Basics/ucm195635.htm. Accessed 1 June 2015.

  6. Nahin RL, Barnes PM, Stussman BJ, Bloom B. Costs of complementary and alternative (CAM) and frequency of visits to CAM practitioners: United States, 2007. Natl Health Stat Report 2009;(18):1–14.

    Google Scholar 

  7. Bradley J. NBJ: the US supplement industry is 37 billion, not $12 billion. http://www.nutraingredients-usa.com/Markets/NBJ-The-US-supplement-industry-is-37-billion-not-12billion/?utm_source=newsletter_daily&utm_medium=email&utm_campaign=01-Jun-2015&c=Ql8IFB6tgmvkRJlzON1mnozAbR4uHGGV&p2=. Accessed 5 June 2015.

  8. Papakostas GI. Evidence for S-adenosyl-l-methionine (SAM-e) for the treatment of major depressive disorder. J Clin Psychiatry. 2009;70 Suppl 5:18–22.

    Article  CAS  PubMed  Google Scholar 

  9. Soeken KL, Lee WL, Bausell RB, Agelli M, Berman BM. Safety and efficacy of S-adenosylmethionine (SAMe) for osteoarthritis. J Fam Pract. 2002;51:425–30.

    PubMed  Google Scholar 

  10. Morelli V, Naquin C, Weaver V. Alternative therapies for traditional disease states: osteoarthritis. Am Fam Physician. 2003;67:339–44.

    PubMed  Google Scholar 

  11. US FDA. Structure/function claims. http://www.fda.gov/Food/IngredientsPackagingLabeling/LabelingNutrition/ucm2006881.htm.

  12. Moyad MA. Dr. Moyad’s no BS diet health advice: a step-by-step guide to what works and what’s worthless. Ann Arbor: Spry Publishing; 2008.

    Google Scholar 

  13. Dysken MW, Sano M, Asthana S, Vertees JE, Pallaki M, Llorente M, et al. Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM-AD VA Cooperative Randomized Trial. JAMA. 2014;311:33–44.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  14. Sano M, Ernesto C, Thomas RG, Klauber MR, Schafer K, Grundman M, et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer’s disease. The Alzheimer’s Disease Cooperative Study. N Engl J Med. 1997;336:1216–22.

    Article  CAS  PubMed  Google Scholar 

  15. Cummings JL, Morstorf T, Zhong K. Alzheimer’s disease drug-development pipeline: few candidates, frequent failures. Alzheimers Res Ther. 2014;6:37. https://my.clevelandclinic.org/about-cleveland-clinic/newsroom/releases-videos-newsletters/cleveland-clinic-researchers-identify-urgent-need-for-alzheimers-disease-drug-development. Accessed 1 June 2015.

    Article  PubMed Central  PubMed  Google Scholar 

  16. Dysken MW, Kirk LN, Kuskowski M. Changes in vitamin E prescribing for Alzheimer patients. Am J Geriatr Psychiatry. 2009;17:621–4.

    Article  PubMed  Google Scholar 

  17. Russ TC, Morling JR. Cholinesterase inhibitors for mild cognitive impairment. Cochrane Database Syst Rev. 2012;9:D009132.

    Google Scholar 

  18. Birks J. Cholinesterase inhibitors for Alzheimer’s disease. Cochrane Database Syst Rev. 2006;1(1):CD005593.

    PubMed  Google Scholar 

  19. Petersen RC, Thomas RG, Grundman M, Bennett D, Doody R, Ferris S, et al., for the Alzheimer Disease Cooperative Study Group. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med 2005;352:2379–88.

    Google Scholar 

  20. Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta-carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol. 2001;119:1417–36.

    Article  PubMed Central  Google Scholar 

  21. Chew EY, Clemons TE, Agron E, Sperduto RD, Sangiovanni JP, Kurinij N, et al., for the Age-Related Eye Disease Study Research Group. Long-term effects of vitamins C and E, β-carotene, and zinc on age-related macular degeneration: AREDS report no. 35. Ophthalmology 2013;120:1604–11.

    Google Scholar 

  22. Age-Related Eye Disease Study 2-AREDS2 Research Group. Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA. 2013;309:2005–15.

    Article  CAS  Google Scholar 

  23. Yoshino J, et al. Resveratrol supplementation does not improve metabolic function in nonobese women with normal glucose tolerance. Cell Metab. 2012;16:658–64.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  24. Popat R, Plesner T, Davies F, et al. A phase 2 study of SRT501 (resveratrol) with bortezomib for patients with relapsed and or refractory multiple myeloma. Br J Haematol. 2013;16:714–7.

    Article  CAS  Google Scholar 

  25. Moyad MA. Complementary medicine for prostate & urologic disease. New York: Springer Publishing; 2014.

    Book  Google Scholar 

  26. Poulsen MM, et al. High-dose resveratrol supplementation in obese men. Diabetes. 2013;62:1186–95.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  27. Wilt TJ, Ishani A, Stark G, MacDonald R, Lau J, Mulrow C. Saw palmetto extracts for treatment of benign prostatic hyperplasia: a systematic review. JAMA. 1998;280:1604–9.

    Article  CAS  PubMed  Google Scholar 

  28. Wilt T, Ishani A, Mac Donald R. Serenoa repens for benign prostatic hyperplasia. Cochrane Database Syst Rev. 2002;3:CD001423.

    PubMed  Google Scholar 

  29. Tacklind J, MacDonald R, Rutks I, Wilt TJ. Serenoa repens for benign prostatic hyperplasia. Cochrane Database Syst Rev. 2009;2:CD001423.

    PubMed  Google Scholar 

  30. MacDonald R, Tacklind JW, Rutks I, Wilt TJ. Serenoa repens monotherapy for benign prostatic hyperplasia (BPH): an updated Cochrane systematic review. BJU Int. 2012;109:1756–61.

    Article  PubMed Central  PubMed  Google Scholar 

  31. Bent S, Kane C, Shinohara K, Neuhaus J, Hudes ES, Goldberg H, et al. Saw palmetto for benign prostatic hyperplasia (BPH). N Engl J Med. 2006;354:557–66.

    Article  CAS  PubMed  Google Scholar 

  32. Barry MJ, Meleth S, Lee JY, Kreder KJ, Avins AL, Nickel JC, et al., for the Complementary and Alternative Medicine for Urological Symptoms (CAMUS) Study Group. Effect of increasing doses of saw palmetto extract on lower urinary tract symptoms: a randomized trial. JAMA 2011;306:1344–51.

    Google Scholar 

  33. Bauer CM, Ishak MB, Johnson EK, Beebe-Dimmer JL, Cooney KA. Prevalence and correlates of vitamin and supplement usage among men with a family history of prostate cancer. Integr Cancer Ther. 2012;11:83–9.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  34. Uzzo RG, Brown JG, Horwitz EM, Hanlon A, Mazzoni S, Konski A, et al. Prevalence and patterns of self-initiated nutritional supplementation in men at high risk of prostate cancer. BJU Int. 2004;93:955–60.

    Article  CAS  PubMed  Google Scholar 

  35. Debruyne F, Koch G, Boyle P, Da Silva FC, Gillenwater JG, Hamdy FC, et al. Comparison of a phytotherapeutic agent (Permixon) with an alpha-blocker (Tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international study. Eur Urol. 2002;41:497–507.

    Article  CAS  PubMed  Google Scholar 

  36. Debruyne F, Boyle P, Calais Da Silva F, Gillenwater JG, Hamdy FC, Perrin P, et al. Evaluation of the clinical benefit of permixon and tamsulosin in severe BPH patients-PERMAL study subset analysis. Eur Urol. 2004;45:773–9.

    Article  CAS  PubMed  Google Scholar 

  37. Raynaud JP, Cousse H, Martin PM. Inhibition of type 1 and type-2 5alpha-reductase activity by free fatty acids, active ingredients of Permixon. J Steroid Biochem Mol Biol. 2002;82:233–9.

    Article  CAS  PubMed  Google Scholar 

  38. Di Silverio F, Monti S, Sclarra A, Varasano PA, Martini C, Lanzara S, et al. Effects of long-term treatment with Serenoa repens (Permixon) on the concentration and regional distribution of androgens and epidermal growth factor in benign prostatic hyperplasia. Prostate. 1998;37:77–83.

    Article  PubMed  Google Scholar 

  39. Nickel JC, Sander S, Moon TD. A meta-analysis of the vascular-related safety profile and efficacy of alpha-adrenergic blockers for symptoms related to benign prostatic hyperplasia. Int J Clin Pract. 2008;62:1547–59.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  40. Roehrborn CG, Siami P, Barkin J, Damiao R, Becher E, Minana B, et al., for the CombAT Study Group. The influence of baseline parameters on changes in international prostate symptom score with dutasteride, tamsulosin, and combination therapy among men with symptomatic benign prostatic hyperplasia and an enlarged prostate: 2-year data from the CombAT study. Eur Urol 2009;55:461–71.

    Google Scholar 

  41. Wagenlehner FM, Weidner W. Prostatitis: no benefit of alpha-blockers for chronic prostatitis. Nat Rev Urol. 2009;6:183–4.

    Article  CAS  PubMed  Google Scholar 

  42. Nickel JC, Krieger JN, McNaughton-Collins M, Anderson RU, Pontari M, Shoskes DA, et al. Alfuzosin and symptoms of chronic prostatitis-chronic pelvic pain syndrome. N Engl J Med. 2008;359:2663–73.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  43. Kristal AR, Darke AK, Morris S, Tangen CM, Goodman PJ, Thompson IM, et al. Baseline selenium status and effects of selenium and vitamin E supplementation on prostate cancer risk. J Natl Cancer Inst. 2014;106(3):djt456.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  44. Mozaffarian D, Marchiolli R, Macchia A, Silletta MG, Ferrazzi P, Gardner TJ, et al. Fish oil and postoperative atrial fibrillation: the Omega-3 Fatty Acids for Prevention of Post-operative Atrial Fibrillation (OPERA) randomized trial. JAMA. 2012;308:2001–11.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  45. Risk and Prevention Study Collaborative Group. N-3 fatty acids in patients with multiple cardiovascular risk factors. N Engl J Med. 2013;368:1800–8.

    Article  CAS  Google Scholar 

  46. Rand AL, Asbell PA. Nutritional supplements for dry eye syndrome. Curr Opin Ophthalmol. 2011;22:279–82.

    Article  PubMed Central  PubMed  Google Scholar 

  47. Foulks GN, Forstot SL, Donshik PC, Goldstein MH, Lemp MA, Nelson JD, et al. Clinical guidelines for management of dry eye associated with Sjogren Disease. Ocul Surf. 2015;13:118–32.

    Article  PubMed  Google Scholar 

  48. Bhargava R, Kumar P. Oral omega-3 fatty acid treatment for dry eye in contact lens wearers. Cornea. 2015;34:413–20.

    Article  PubMed  Google Scholar 

  49. Liu A, Ji J. Omega-3 essential fatty acids therapy for dry eye syndrome: a meta-analysis of randomized controlled studies. Med Sci Monit. 2014;20:1583–9.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  50. DREAM (Dry Eye Assessment and Management) Clinical Trial. https://clinicaltrials.gov/ct2/show/NCT02128763?term=dream%26rank=5. Accessed 1 June 2015.

  51. Fish 101. http://www.heart.org/HEARTORG/GettingHealthy/NutritionCenter/Fish-101_UCM_305986_Article.jsp#aha_recommendation. Accessed 1 June 2015.

  52. Blair HA, Dhillon S. Omega-3 carboxylic acids (Epanova): a review of its use in patients with severe hypertriglyceridemia. Am J Cardiovasc Drugs. 2014;14:393–400.

    Article  CAS  PubMed  Google Scholar 

  53. Zhao A, Lam S. Omega-3-carboxylic acid (epanova) for hypertriglyceridemia. Cardiol Rev. 2015;23:148–52.

    PubMed  Google Scholar 

  54. Cormio L, De Siati M, Lorusso F, Selvaggio O, Mirabella L, Sanguedolce F, et al. Oral-l-citrulline supplementation improves erection hardness in men with mild erectile dysfunction. Urology. 2011;77:119–22.

    Article  PubMed  Google Scholar 

  55. Wax B, Kavazis AN, Weldon K. Sperlak. J Strength Cond Res. 2015;29:786–92.

    Article  PubMed  Google Scholar 

  56. Liu J, Zhang J, Shi Y, et al. Chinese red yeast rice (Monascus purpureus) for primary hyperlipidemia: a meta-analysis of randomized controlled trials. Chin Med. 2006;1:4.

    Article  PubMed Central  PubMed  Google Scholar 

  57. China Coronary Secondary Prevention Study Group. China coronary secondary prevention study (CCSPS)-Lipid regulating therapy with xuezhikang for secondary prevention of coronary heart disease. Chin J Cardiol (Chin). 2005;33:109–15.

    Google Scholar 

  58. Ong HT. The statin studies: from targeting hypercholesterolemia to targeting the high risk patient. QJM. 2005;98:599–614.

    Article  CAS  PubMed  Google Scholar 

  59. Zhao SP, Lu ZL, Du BM, et al., Xuezhikang, an extract of cholestin, reduces cardiovascular events in type 2 diabetes patients with coronary heart disease: subgroup analysis of patients with type 2 diabetes from China Coronary Secondary Prevention Study (CCSPS). J Cardiovasc Pharmacol 2007;49:81–4.

    Google Scholar 

  60. Ye P, Lu ZL, Du BM, et al., for the CCSPS Investigators. Effects of xuezhikang on cardiovascular events and mortality in elderly patients with a history of myocardial infarction: a subgroup analysis of elderly subjects from China coronary secondary prevention study. J Am Geriatr Soc 2007;55:1015–22.

    Google Scholar 

  61. Li JJ, Lu ZL, Kou WR, et al., for the Chinese Coronary Secondary Prevention Study (CCSPS) Group. Long-term effects of Xuezhikang on blood pressure in hypertensive patients with previous myocardial infarction: data from the Chinese Coronary Secondary Prevention Study (CCSPS). Clin Exp Hypertens 2010;32(8):491–8.

    Google Scholar 

  62. Huang CF, Li TC, Lin CC, et al. Efficacy of Monascus purpureus Went rice on lowering lipid ratios in hypercholesterolemic patients. Eur J Cardiovasc Prev Rehabil. 2007;14:438–40.

    Article  PubMed  Google Scholar 

  63. Lin CC, Li TC, Lai MM. Efficacy and safety of Monascus purpureus Went rice in subjects with hyperlipidemia. Eur J Endocrinol. 2005;153:679–86.

    Article  CAS  PubMed  Google Scholar 

  64. Heber D, Yip I, Ashley JM, et al. Cholesterol-lowering effects of a proprietary Chinese red-yeast-rice dietary supplement. Am J Clin Nutr. 1999;69:231–6.

    CAS  PubMed  Google Scholar 

  65. Moyad MA, Klotz LH. Statin clinical trial (REALITY) for prostate cancer: an over 15-year wait is finally over thanks to a dietary supplement. Urol Clin North Am. 2011;38:325–31.

    Article  PubMed  Google Scholar 

  66. Zanardi M, Quirico E, Benvenuti C, Pezzana A. Use of a lipid-lowering food supplement in patients on hormone therapy following breast cancer. Minerva Ginecol. 2012;64:431–5.

    CAS  PubMed  Google Scholar 

  67. Poole C, Bushey B, Foster C, Campbell B, Willoughby D, Kreider R, et al. The effects of a commercially available botanical supplement on strength, body composition, power output, and hormonal profiles in resistance-trained males. J Int Soc Sports Nutr. 2010;7:34.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  68. Lyseng-Williamson KA. Melatonin prolonged release: in the treatment of insomnia in patients aged ≥55 years. Drugs Aging. 2012;29:911–23.

    Article  CAS  PubMed  Google Scholar 

  69. Chen WY, Giobbie-Hurder A, Gantman K, Savoie J, Scheib R, Parker LM, et al. A randomized, placebo-controlled trial of melatonin on breast cancer survivors: impact on sleep, mood, and hot flashes. Breast Cancer Res Treat. 2014;145:381–8.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  70. Hansen MV, Andersen LT, Madsen MT, Hagerman I, Rasmussen LS, Bokmand S, et al. Effect of melatonin on depressive symptoms and anxiety in patients undergoing breast cancer surgery: a randomized, double-blind, placebo-controlled trial. Breast Cancer Res Treat. 2014;145:683–95.

    Article  CAS  PubMed  Google Scholar 

  71. FDA Drug Safety Communication: FDA warns of next-day impairment with sleep aid Lunesta (eszopiclone) and lowers recommended dose. http://www.fda.gov/Drugs/DrugSafety/ucm397260.htm. Accessed 1 June 2015.

  72. Holland S, et al., for the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Evidence-based guideline update: NSAIDs and other complementary treatments for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology 2012;78:1346–53.

    Google Scholar 

  73. Parkinson Study Group SURE-PD Investigators. Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial. JAMA Neurol. 2014;71:141–50.

    Article  Google Scholar 

  74. Elm JJ, NINDS NET-PD Investigators. Design innovations and baseline findings in a long-term Parkinson’s Trial: the National Institute of Neurological Disorders and Stroke Exploratory Trials in Parkinson’s Disease Long-Term Study-1. Mov Disord. 2012;27:1513–21.

    Article  CAS  PubMed  Google Scholar 

  75. Writing Group for the NINDS Exploratory Trials in Parkinson Disease (NET-PD) Investigators. Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: a randomized clinical trial. JAMA. 2015;313:584–93.

    Article  CAS  Google Scholar 

  76. Jepson RG, Williams G, Craig JC. Cranberries for preventing urinary tract infections. Cochrane Database Syst Rev. 2012;10:CD001321.

    PubMed  Google Scholar 

  77. Micali S, Isgro G, Bianchi G, Miceli N, Calapai G, Navarra M. Cranberry and recurrent cystitis: more than marketing? Crit Rev Food Sci Nutr. 2014;54:1063–75.

    Article  CAS  PubMed  Google Scholar 

  78. Ledda A, Bottari A, Luzzi R, Belcaro G, Hu S, Dugall M, et al. Cranberry supplementation in the prevention of non-severe lower urinary tract infections: a pilot study. Eur Rev Med Pharmacol Sci. 2015;19:77–80.

    CAS  PubMed  Google Scholar 

  79. Caljouw MA, van den Hout WB, Putler H, Achterberg WP, Cools HJ, Gussekloo J. Effectiveness of cranberry capsules to prevent urinary tract infections in vulnerable older persons: a double-blind randomized placebo-controlled trial in long-term care facilities. J Am Geriatr Soc. 2014;62:103–10.

    Article  PubMed  Google Scholar 

  80. Miller PE, Alexander DD, Perez V. Effects of whey protein and resistance exercise on body composition: a meta-analysis of randomized controlled trials. J Am Coll Nutr. 2014;33:163–75.

    Article  CAS  PubMed  Google Scholar 

  81. Jones PJ, AbuMweis SS. Phytosterols as functional food ingredients: linkages to cardiovascular disease and cancer. Curr Opin Clin Nutr Metab Care. 2009;12:147–51.

    Article  CAS  PubMed  Google Scholar 

  82. Berryman CE, Preston AG, Karmally W, Deckelbaum RJ, Kris-Etherton PM. Effects of almond consumption on the reduction of LDL-cholesterol: a discussion of potential mechanisms and future research directions. Nutr Rev. 2011;69:171–85.

    Article  PubMed  Google Scholar 

  83. Aldemir M, Okulu E, Neselioglu S, Erel O, Kayigil O. Pistachio diet improves erectile function parameters and serum lipid profiles in patients with erectile dysfunction. Int J Impot Res. 2011;23:32–8.

    Article  CAS  PubMed  Google Scholar 

  84. Guardamagna O, Abello F, Baracco V, et al. Primary hyperlipidemias in children: effect of plant sterol supplementation on plasma lipids and markers of cholesterol synthesis and absorption. Acta Diabetol. 2011;48(2):127–33. Epub 6 Nov 2010.

    Article  CAS  PubMed  Google Scholar 

  85. Malinkowski JM, Gehret MM. Phytosterols for dyslipidemia. Am J Health Syst Pharm. 2010;67:1165–73.

    Article  CAS  Google Scholar 

  86. Hamilton P. Role of ezetimibe in the management of patients with atherosclerosis. Coron Artery Dis. 2009;20:169–74.

    Article  PubMed  Google Scholar 

  87. Dujovne CA, Suresh R, McCrary Sisk C, et al. Safety and efficacy of ezetimibe monotherapy in 1624 primary hypercholesterolaemic patients for up to 2 years. Int J Clin Pract. 2008;62:1332–6.

    Article  CAS  PubMed  Google Scholar 

  88. Pelton K, Di Vizio D, Insabato L, et al. Ezetimibe reduces enlarged prostate in an animal model of benign prostatic hyperplasia. J Urol. 2010;184:1555–9.

    Article  CAS  PubMed  Google Scholar 

  89. Mills IW, Crossland A, Patel A, Ramonas H. Atorvastatin treatment for men with lower urinary tract symptoms and benign prostatic enlargement. Eur Urol. 2007;52:503–9.

    Article  CAS  PubMed  Google Scholar 

  90. Stamatiou KN, Zaglavira P, Skolarikos A, Sofras F. The effects of lovastatin on conventional medical treatment of lower urinary tract symptoms with finasteride. Int Braz J Urol. 2008;34:555–61.

    Article  PubMed  Google Scholar 

  91. Hall SA, Chiu GR, Link CL, et al. Are statin medications associated with lower urinary tract symptoms in men and women? Results from the Boston Area Community Health (BACH) Survey. Ann Epidemiol. 2011;21:149–55.

    Article  PubMed Central  PubMed  Google Scholar 

  92. St Sauver JL, Jacobsen SJ, Jacobson DJ, et al. Statin use and decreased risk of benign prostatic enlargement and lower urinary tract symptoms. BJU Int. 2011;107:443–50.

    Article  PubMed Central  PubMed  Google Scholar 

  93. Padayatty SJ, Marcelli M, Shao TC, Cunningham GR. Lovastatin-induced apoptosis in prostate stromal cells. J Clin Endocrinol Metab. 1997;82:1434–9.

    Article  CAS  PubMed  Google Scholar 

  94. Freeman MR, Solomon KR. Cholesterol and benign prostate disease. Differentiation. 2011;82:244–52.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  95. Wilt TJ, Macdonald R, Ishani A. B-sitosterol for the treatment of benign prostatic hyperplasia: a systematic review. BJU Int. 1999;83:976–83.

    Article  CAS  PubMed  Google Scholar 

  96. Wilt TJ, Ishani A, MacDonald R, Stark G, Mulrow CD, Lau J. Beta-sitosterols for benign prostatic hyperplasia. Cochrane Database Syst Rev. 2000;2:CD001043.

    PubMed  Google Scholar 

  97. Kadow C, Abrams PH. A double-blind trial of the effect of beta-sitosteryl glucoside (WA184) in the treatment of benign prostatic hyperplasia. Eur Urol. 1986;12:187–9.

    CAS  PubMed  Google Scholar 

  98. Fischer A, Jurincic-Winkler CD, Klippel KF. Conservative treatment of benign prostatic hyperplasia with high-dosage b-sitosterol (65 mg): results of a placebo-controlled double-blind study. Uroscopy. 1993;1:12–20.

    Google Scholar 

  99. Berges RR, Windeler J, Trampisch HJ, Senge T. Randomised, placebo-controlled, double-blind clinical trial of beta-sitosterol in patients with benign prostatic hyperplasia. Beta-sitosterol Study Group. Lancet. 1995;345(8964):1529–32.

    Article  CAS  PubMed  Google Scholar 

  100. Kippel KF, Hiltl DM, Schipp B. A multicentric, placebo-controlled, double-blind clinical trial of b-sitosterol (phytosterol) for the treatment of benign prostatic hyperplasia. Br J Urol. 1997;80:427–32.

    Article  Google Scholar 

  101. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143–421.

    Google Scholar 

  102. Grattan Jr BJ. Plant sterols as anticancer nutrients: evidence for their role in breast cancer. Nutrients. 2013;5:359–87.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  103. Cannon CP, Blazing MA, Giugilano RP, McCagg A, White JA, Theroux P, et al., for the IMPROVE-IT investigators. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015;372(25):2387–97, Epub 3 June 2015.

    Google Scholar 

  104. Solomon KR, Pelton K, Boucher K, Joo J, Tully C, Zurakowski D, et al. Ezetimibe is an inhibitor of tumor angiogenesis. Am J Pathol. 2009;174:1017–26.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  105. Ruiz ME. Risks of self-medication practices. Curr Drug Saf. 2010;5:315–23.

    Article  PubMed  Google Scholar 

  106. McRorie JW, Kirby JA, Miner PB. Histamine2-receptor antagonists: rapid development of tachyphylaxis with repeat dosing. World J Gastrointest Pharmacol Ther. 2014;5:57–62.

    PubMed Central  PubMed  Google Scholar 

  107. Targum SD. Identification and treatment of antidepressant tachyphylaxis. Innov Clin Neurosci. 2014;11(3–4):24–8.

    PubMed Central  PubMed  Google Scholar 

  108. Cromwell WC, Ziajka PE. Development of tachyphylaxis among patients taking HMG CoA reductase inhibitors. Am J Cardiol. 2000;86:1123–7.

    Article  CAS  PubMed  Google Scholar 

  109. Klemenska E, Beresewicz A. Bioactivation of organic nitrates and the mechanism of nitrate tolerance. Cardiol J. 2009;16:11–9.

    PubMed  Google Scholar 

  110. Malczewska-Malec M, Goldsztajn P, Kawecka-Jaszcz K, Czamecka D, Siedlecki A, Siemienska T, et al. Effects of prolonged l-arginine administration on blood pressure in patients with essential hypertension (EH). Agents Actions Suppl. 1995;45:157–62.

    CAS  PubMed  Google Scholar 

  111. Manson JE, Bassuk SS. Calcium supplements: do they help or harm? Menopause. 2014;21:106–8.

    Article  PubMed  Google Scholar 

  112. Thomas LDK, Elinder C-G, Tiselius H-G, Wolk A, Akesson A. Ascorbic acid supplements and kidney stone incidence among men: a prospective study. JAMA Intern Med. 2013;173:386–8.

    Article  PubMed  Google Scholar 

  113. Dag MS, Ozurk ZA, Akin I, Tutar E, Cikman O, Gulsen MT. Drug-induced esophageal ulcers: case series and the review of the literature. Drug-induced esophageal ulcers: case series and the review of the literature. Turk J Gastroenterol. 2014;25:180–4.

    Article  PubMed  Google Scholar 

  114. Gallego Perez B, Martinez Crespo JJ, Garcia Belmonte D, Marin Bernabe CM. l-Arginine pill induced esophageal ulcer: causes not reported previously esophagitis for pills. Farm Hosp. 2014;38:487–9.

    PubMed  Google Scholar 

  115. Flythe JE, Rueda JF, Riscoe MK, Watnick S. Silicate nephrolithiasis after ingestion of supplements containing silica dioxide. Am J Kidney Dis. 2009;54:127–30.

    Article  PubMed  Google Scholar 

  116. National Public Radio (NPR) website. Feds say it’s time to cut back on fluoride in drinking water. http://www.npr.org/sections/health-shots/2015/04/27/402579949/feds-say-its-time-to-cut-back-on-fluoride-in-drinking-water. Accessed 1 June 2015.

  117. Proton Pump Inhibitors Information. US Food and Drug Administration. http://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm213259.htm. Accessed 1 June 2015.

  118. Moyad MA. Heart healthy = prostate healthy: SELECT, the symbolic end of preventing prostate cancer via heart unhealthy and over anti-oxidation mechanisms? Asian J Androl. 2012;14:243–4.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  119. Jackson RD, LaCroix AZ, Gass M, Wallace RB, Robbins J, Lewis CE, et al. Calcium and vitamin D supplementation and the risk of fractures. N Engl J Med. 2006;354:669–83.

    Article  CAS  PubMed  Google Scholar 

  120. Zhang Z, Cogswell ME, Gillespie C, Fang J, Loustalot F, Dai S, et al. Association between usual sodium and potassium intake and blood pressure and hypertension among U.S. adults: NHANES 2005–2010. PLoS One. 2013;8:e75289.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  121. WHO website. http://whqlibdoc.who.int/trs/who_trs_916.pdf. Accessed 1 June 2015.

  122. Svetkey LP, Simons-Morton D, Vollmer WM, Appel LJ, Conlin PR, Ryan DH, et al. Effects of dietary patterns on blood pressure: subgroup analysis of the Dietary Approaches to Stop Hypertension (DASH) randomized clinical trial. Arch Intern Med. 1999;159:285–93.

    Article  CAS  PubMed  Google Scholar 

  123. Mankowski RT, Anton SD, Buford TW, Leeuwenburgh C. Dietary antioxidants as modifiers of physiologic adaptations to exercise. Med Sci Sports Exerc 2015, Epub ahead of print.

    Google Scholar 

  124. Olesen J, Gilemann L, Bienso R, Schmidt J, Hellsten Y, Pilegaard H. Exercise training, but not resveratrol, improves metabolic and inflammatory status in skeletal muscle of aged men. J Physiol. 2014;592(Pt 8):1873–86.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  125. Andersen MB, Pingel J, Kjaer M, Langberg H. Interleukin-6: a growth factor stimulating collagen synthesis in human tendon. J Appl Physiol. 2011;110:1549–54.

    Article  CAS  PubMed  Google Scholar 

  126. Valero T. Mitochondrial biogenesis: pharmacological approaches. Curr Pharm Des. 2014;20:5507–9.

    Article  CAS  PubMed  Google Scholar 

  127. Kruger K, Mooren FC. Exercise-induced leukocyte apoptosis. Exerc Immunol Rev. 2014;20:117–34.

    PubMed  Google Scholar 

  128. Harijith A, Ebenezer DL, Natarajan V. Reactive oxygen species at the crossroads of inflammasome and inflammation. Front Physiol. 2014;5:352.

    Article  PubMed Central  PubMed  Google Scholar 

  129. Taghipour N, Aghdael HA, Haghighi A, Mossafa N, Tabaei SJ, Rostami-Nejad M. Potential treatment of inflammatory bowel disease: a review of helminthes therapy. Gastroenterol Hepatol Bed Bench. 2014;7:9–16.

    PubMed Central  PubMed  Google Scholar 

  130. Rutkowski K, Sowa P, Rutkowska-Talipska J, Sulkowski S, Rutkowski R. Allergic diseases: the price of civilizational progress. Postepy Dermatol Alergol. 2014;31:77–83.

    Article  PubMed Central  PubMed  Google Scholar 

  131. Venditti O, De Lisi D, Caricato M, Caputo D, Capolupo GT, Taffon C, et al. Ipilimumab and immune-mediated adverse events: a case report of anti-CTLA4 induced ileitis. BMC Cancer. 2015;15:87.

    Article  PubMed Central  PubMed  Google Scholar 

  132. Gaziano JM, Sesso HD, Christen WG, Bubes V, Smith JP, MacFadyen J, et al. Multivitamins in the prevention of cancer in men: the Physicians’ Health Study II randomized controlled trial. JAMA. 2012;308:1871–80.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  133. US Food and Drug Administration. Facts about the current good manufacturing practices (cGMPs). http://www.fda.gov/Food/GuidanceRegulation/CGMP/ucm079496.htm. http://www.fda.gov/Drugs/DevelopmentApprovalProcess/Manufacturing/ucm169105.htm. Accessed 1 June 2015.

  134. NSF International. www.nsf.org. Accessed 1 June 2015.

  135. Informed Choice. http://www.informed-choice.org/registered-products. Accessed 1 June 2015.

  136. USP-US Pharmacopeial Convention. www.usp.org. Accessed 1 June 2015.

  137. Natural Products Association. www.npainfo.org. Accessed 1 June 2015.

  138. Barton DL, Liu H, Dakhil SR, Linquist B, Sloan JA, Nichols CR, et al. Wisconsin ginseng (Panax quinquefolius) to improve cancer-related fatigue: a randomized, double-blind trial, N07C2. J Natl Cancer Inst. 2013;105(16):1230–8.

    Article  PubMed Central  PubMed  Google Scholar 

  139. Barton DL, Soori GS, Bauer BA, Sloan JA, Johhnson PA, Figuera C, et al. Pilot study of Panax quinquefolius (American ginseng) to improve cancer-related fatigue: a randomized, double-blind, dose-finding evaluation: NCCTG trial N03CA. Support Cancer Care. 2010;18:179–87.

    Article  Google Scholar 

  140. Ruddy KJ, Barton D, Loprinzi CL. Laying to rest psychostimulants for cancer-related fatigue? J Clin Oncol. 2014;32:1865–7.

    Article  CAS  PubMed  Google Scholar 

  141. Yennurajalingham S, Reddy A, Tannir NM, Chisholm GB, Lee RT, Lopez G, et al. High-dose Asian ginseng (Panax Ginseng) for cancer-related fatigue: a preliminary report. Integr Cancer Ther 2015, Epub ahead of print.

    Google Scholar 

  142. Ryan JL, Heckler CE, Roscoe JA, Dakhil SR, Kirshner J, Flynn PJ, et al. Ginger (Zingiber officinale) reduces acute chemotherapy-induced nausea: a URCC CCOP study of 576 patients. Support Care Cancer. 2012;20:1479–89.

    Article  PubMed Central  PubMed  Google Scholar 

  143. Zindol® for chemotherapy induced nausea and vomiting. http://www.aphios.com/products/therapeutic-product-pipeline/oncology/zindol.html. Accessed 1 June 2015.

  144. Zindol® DS. http://www.aphioshwc.com/products/zindol-ds.html. Accessed 1 June 2015.

  145. Hercberg S, Galen P, Preziosi P, Bertrais S, Mennen L, Malvy D, et al. The SU.VI.MAX Study: a randomized, placebo-controlled trial of the health effects of antioxidant vitamins and minerals. Arch Intern Med. 2004;164:2335–42.

    Article  CAS  PubMed  Google Scholar 

  146. Fransen M, Agallotis M, Nairn L, Votrubec M, Bridgett L, Su S, et al. Glucosamine and chondroitin for knee osteoarthritis: a double-blind randomized placebo-controlled clinical trial evaluating single and combination regimens. Ann Rheum Dis. 2015;74:851–8.

    Article  CAS  PubMed  Google Scholar 

  147. Yim SH, Chung YJ. Reflections on the US FDA’s warning on direct-to-consumer genetic testing. Genomics Inform. 2014;12:151–5.

    Article  PubMed Central  PubMed  Google Scholar 

  148. Wallace ML, Ricco JA, Barrett B. Screening strategies for cardiovascular disease in asymptomatic adults. Prim Care. 2014;41:371–97.

    Article  PubMed Central  PubMed  Google Scholar 

  149. Gadkari AS, McHorney CA. Unintentional non-adherence to chronic prescription medications: how unintentional is it really? BMC Health Serv Res. 2012;12:98.

    Article  PubMed Central  PubMed  Google Scholar 

  150. Harvey LJ, Dainty JR, Hollands WJ, Bull VJ, Hoogewerff JA, Foxall RJ, et al. Effect of high-dose iron supplements on fractional zinc absorption and status in pregnant women. Am J Clin Nutr. 2007;85:131–6.

    CAS  PubMed  Google Scholar 

  151. Alleyne M, Horne MK, Miller JL. Individualized treatment for iron-deficiency anemia in adults. Am J Med. 2008;121:943–8.

    Article  PubMed Central  PubMed  Google Scholar 

  152. Diabetes Prevention Program Research Group. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet. 2009;374:1677–86.

    Article  PubMed Central  Google Scholar 

  153. Taylor F, Huffman MD, Macedo AF, Moore TH, Burke M, Davey Smith G, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2013;1:CD004816.

    PubMed  Google Scholar 

  154. Kennedy SP, Barnas GP, Schmidt MJ, Glisczinski MS, Paniagua AC. Efficacy and tolerability of once-weekly rosuvastatin in patients with previous statin intolerance. J Clin Lipidol. 2011;5:308–15.

    Article  PubMed  Google Scholar 

  155. Watts NB, Diab DL. Long-term use of bisphosphonates in osteoporosis. J Clin Endocrinol Metab. 2010;95:1555–65.

    Article  CAS  PubMed  Google Scholar 

  156. Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt SA, for the FLEX Research Group. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA. 2006;296:2927–38.

    Article  CAS  PubMed  Google Scholar 

  157. Navarro VJ, Barnhart H, Bonkovsky HL, Davern T, Fontana RJ, Grant L, et al. Liver injury from herbals and dietary supplements in the US Drug-induced Liver Injury Network. Hepatology. 2014;60:1399–408.

    Article  PubMed Central  PubMed  Google Scholar 

  158. Lee Y, Mitchell DC, Smiciklas-Wright H, Birch LL. Maternal influences on 5- to 7-year old girls’ intake of multivitamin-mineral supplements. Pediatrics. 2002;109:E46.

    Article  PubMed Central  PubMed  Google Scholar 

  159. Sien YP, Sahril N, Abdul Mutalip MH, Zaki NA, Abdul Ghaffar S. Determinants of dietary supplements use among adolescents in Malaysia. Asia Pac J Public Health. 2014;26(5 Suppl):36S–43.

    Article  PubMed  Google Scholar 

  160. Wu CH, Wang CC, Kennedy J. The prevalence of herb and dietary use among children and adolescents in the United States: Results from the 2007 National Health Interview Survey. Complement Ther Med. 2013;21:358–63.

    Article  PubMed  Google Scholar 

  161. Korownyk C, Kolber MR, McCormack J, Lam V, Overbo K, Cotton C, et al. Televised medical talk shows-what they recommend and the evidence to support their recommendations: a prospective observational study. BMJ. 2014;349:g7346.

    Article  PubMed Central  PubMed  Google Scholar 

  162. Petadolex. www.petadolex.com. Accessed 1 June 2015.

  163. Sylvan Bio. www.sylvaninc.com/bio/healthCare.html. Accessed 1 June 2015.

  164. Becker DJ, Gordon RY, Halbert SC, French B, Morris PB, Rader DJ. Red yeast rice for dyslipidemia in statin-intolerant patients: a randomized trial. Ann Intern Med. 2009;150:830–9.

    Article  PubMed  Google Scholar 

  165. Phamavite. www.pharmavite.com. Accessed 1 June 2015.

  166. Papakostas GI, Mischoulon D, Shyu I, Alpert JE, Fava M. S-adenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder: a double-blind, randomized, clinical trial. Am J Psychiatry. 2010;167:942–8.

    Article  PubMed  Google Scholar 

  167. Align. www.aligngi.com. Accessed 1 June 2015.

  168. Brenner DM, Chey WD. Bifidobacterium infantis 35624: a novel probiotic for the treatment of irritable bowel syndrome. Rev Gastroenterol Disord. 2009;9:7–15.

    PubMed  Google Scholar 

  169. US Food and Drug Administration. http://www.accessdata.fda.gov/scripts/enforcement/enforce_rpt-Event-Detail.cfm?action=detail&id=66557&w=11202013&lang=eng. Accessed 1 June 2015.

  170. US Food Safety. Dietary supplements recall for the potential of chloramphenicol. http://blog.usfoodsafety.com/2014/01/10/dietary-supplements-recall-for-the-potential-of-chloramphenicol/. Accessed 1 June 2015.

  171. Gokmen MR, Cosyns J-P, Arit VM, Stiborova M, Phillips DH, Schmeiser HH, et al. The epidemiology, diagnosis, and management of aristolochic acid nephropathy. Ann Intern Med. 2013;158:469–77.

    Article  PubMed  Google Scholar 

  172. US Food and Drug Administration. Dietary supplements: aristolochic acid. Silver Spring, MD: US Food and Drug Administration; 2001. www.fda.gov/Food/DietarySupplements/Alerts/ucm095272.htm. Accessed 1 June 2015.

    Google Scholar 

  173. Allen JA, Peterson A, Sufit R, Hinchcliff ME, Mahoney JM, Wood TA, et al. Post-epidemic eosinophilia-myalgia syndrome associated with l-tryptophan. Arthritis Rheum. 2011;63:3633–9.

    Article  CAS  PubMed  Google Scholar 

  174. Park City Group and Repositrak. www.repositrak.com or www.parkcitygroup.com. Accessed 1 June 2015.

  175. DNA TREK. www.dnatrek.co. Accessed 1 June 2015.

Download references

Author information

Authors and Affiliations

  1. Department of Urology, University of Michigan Medical Center, Ann Arbor, Michigan, USA

    Mark A. Moyad MD, MPH

  2. Jenkins/Pokempner Director of Complementary & Alternative Medicine, University of Michigan Medical Center (Dept of Urology), Ann Arbor, MI, USA

    Mark A. Moyad MD, MPH

Authors
  1. Mark A. Moyad MD, MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Moyad, M.A. (2016). 25+ Observations Over 25+ Years for Surviving and Thriving in the Dietary Supplement Quality Control and/or Perception Versus Reality World. In: Integrative Medicine for Breast Cancer. Springer, Cham. https://doi.org/10.1007/978-3-319-23422-9_2

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-23422-9_2

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-23421-2

  • Online ISBN: 978-3-319-23422-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation